Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy

Gomez-Gelvez, Juan C.; Salama, Mohamed E.; Perkins, Sherrie L.; Leavitt, Matthew; Inamdar, Kedar

doi:10.1093/ajcp/aqw034

Cited by 36 publications

(56 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean MVD in the RCHOP group with events was 154.7/mm 2 and that in the CHOP group was 349.2/mm. 2 Median of CD34 was 37 in a study by Ruan et al 11 Our findings correlate with the study by Perry et al, who attempted to simulate the stromal-2 signature by measuring MVD in DLBCL and found high MVD to be an unfavorable prognostic factor. 14 The stromal-2 signature is expressed by genes regulating endothelial proliferation through vascular endothelial growth factor (VEGF) receptor, TEK (tyrosine kinase, endothelial), and ERG V-ets (erythroblastosis virus E26 oncogene homolog gene).…”

Section: Fig 1 Immunohistochemistry For Cd34 Highlighting Microvessesupporting

confidence: 87%

“…The study by Gomez-Gelvez et al showed that CD34 is the best stain owing to its clean background, and positive staining cells/cell groups with or without lumen formation represent microvessels. 2 Therefore, we too did CD34 staining and counting using image analysis. MVD is the measure used to assess the angiogenesis in tumors including lymphomas.…”

Section: Fig 1 Immunohistochemistry For Cd34 Highlighting Microvessementioning

confidence: 99%

“…As the tumor does not show significant morphological variations, heterogenous biology most likely results in this varied outcome. 2 Numerous immunohistochemical (IHC) and molecular studies have been conducted on the tumor cells in order to find out this difference in behavior. 3 Recently, the tumor microenvironment has gained importance, as it is suggested that the crosstalk between the tumor cells and the cells in the microenvironment plays a crucial role in the tumor biology by Lenz et al 4 CD68 is among the several markers for macrophages that form a component of stromal-1 signature.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immunohistochemical Markers of Tumor Microenvironment as Prognostic Predictors in Diffuse Large B-Cell Lymphoma: Study from an Oncology Centre in South India

Nair

Sadeesh

Phalak

et al. 2021

ASJO

View full text Add to dashboard Cite

Abstract Introduction Diffuse large B-cell lymphoma (DLBCL) accounts for 60% of lymphomas in India. Although the survival of DLBCL patients has improved following the addition of rituximab, a subset of patients do not respond well to therapy. Among the several factors responsible for this varied response, tumor microenvironment is considered to be crucial. This study is a search for such prognostic markers in the tumor microenvironment. Materials and Methods A total of 97 patients were selected, of whom 34 were treated with the CHOP regimen and 63 with RCHOP. Immunohistochemistry for CD68 was performed to study the stromal-1 signature and CD34 for stromal-2 signature. Results There was a significant increase in the counts of CD68-positive cells among patients free of events. CD34 count was higher in patients with events in both CHOP and RCHOP groups. Conclusion Additional assessment of stromal microenvironment along with the cell of origin might predict the clinical outcome better in DLBCL.

show abstract

Section: Fig 1 Immunohistochemistry For Cd34 Highlighting Microvessesupporting

confidence: 87%

Section: Fig 1 Immunohistochemistry For Cd34 Highlighting Microvessementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemical Markers of Tumor Microenvironment as Prognostic Predictors in Diffuse Large B-Cell Lymphoma: Study from an Oncology Centre in South India

Nair

Sadeesh

Phalak

et al. 2021

ASJO

View full text Add to dashboard Cite

show abstract

“…One of the main functions of Tregs is the regulation of antitumor immune responses by inhibiting the cytokine production and suppressing the proliferation of CD8 + T cells, which may lead to an ineffective antitumor response and to the proliferation of cancer cells [37][38][39]. In DLBCL, the prognostic influence of FOXP3 + Treg is controversial, reported as being associated with a good prognosis in some studies or with an adverse outcome [40][41][42] or a trend toward a worse prognosis in other studies [43].…”

Section: Immune Evasionmentioning

confidence: 99%

Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis

Cioroianu

Stînga

Sticlaru

et al. 2019

Analytical Cellular Pathology

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) represents 30-40% of all non-Hodgkin lymphomas (NHL) and is a disease with an aggressive behavior. Because about one-third of DLBCL patients will be refractory or resistant to standard therapy, several studies focused on identification of new individual prognostic and risk stratification biomarkers and new potential therapeutic targets. In contrast to other types of cancers like carcinomas, where tumor microenvironment was widely investigated, its role in DLBCL pathogenesis and patient survival is still poorly understood, although few studies had promising results. The composition of TME and its interaction with neoplastic cells may explain the role of several genes (beta2-microglobulin gene, CD58 gene), receptor-like programmed cell death-1 (PD-1) and its ligand (PD-L1), or other cell components (Treg) in tumor evasion of immune surveillance, resulting in tumor progression. Also, it was found that “gene expression profile” of the microenvironmental cells, the phenotype of tumor-associated macrophages (TAM), the expression of matricellular proteins like SPARC and fibronectin, the overexpression of several types of matrix metalloproteinases (MMPs) like MMP-2 and MMP-9, or the tissue inhibitors of matrix metalloproteinases (TIMPs) may lead to a favorable or adverse outcome. With this review, we try to highlight the influence of microenvironment components over lymphoid clone progression and their prognostic impact in DLBCL patients.

show abstract

“…The mechanisms by which mast cells reduce the efficacy of antibody-based therapies in FL remain to be determined and might include the negative regulation of macrophage activity and antibody-dependent cellular cytotoxicity through the expression of Fc receptors which can engage rituximab [62]. Tissue microarray immunohistochemistry with automated scoring of FoxP3, CD68 and microvessel (CD34) density (MVD) has been shown to stratify patients with DLBCL into risk groups and to predict prognosis [66]. Patients in the high-risk group had significantly worse EFS and PFS, suggesting that TME components should be considered as an important tool to predict patient survival.…”

Section: Chronic Myeloid Leukaemia Targeted Treatment With Tyrosine mentioning

confidence: 99%

Discovery and application of immune biomarkers for hematological malignancies

Zafeiris

Vadakekolathu

Wagner

et al. 2017

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Hematological malignancies originate and progress in primary and secondary lymphoid organs, where they establish a uniquely immune-suppressive tumour microenvironment. Although high-throughput transcriptomic and proteomic approaches are being employed to interrogate immune surveillance and escape mechanisms in patients with solid tumours, and to identify actionable targets for immunotherapy, our knowledge of the immunological landscape of hematological malignancies, as well as our understanding of the molecular circuits that underpin the establishment of immune tolerance, is not comprehensive. Areas covered: This article will discuss how multiplexed immunohistochemistry, flow cytometry/mass cytometry, proteomic and genomic techniques can be used to dynamically capture the complexity of tumour-immune interactions. Moreover, the analysis of multi-dimensional, clinically annotated data sets obtained from public repositories such as Array Express, TCGA and GEO is crucial to identify immune biomarkers, to inform the rational design of immune therapies and to predict clinical benefit in individual patients. We will also highlight how artificial neural network models and alternative methodologies integrating other algorithms can support the identification of key molecular drivers of immune dysfunction. Expert commentary: High-dimensional technologies have the potential to enhance our understanding of immune-cancer interactions and will support clinical decision making and the prediction of therapeutic benefit from immune-based interventions.

show abstract

Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy

Abstract: The concomitant evaluation of cell of origin along with tumor microenvironment components identifies patients with DLBCL treated with R-CHOP chemotherapy portraying a worse prognosis.

Cited by 36 publications

References 39 publications

Immunohistochemical Markers of Tumor Microenvironment as Prognostic Predictors in Diffuse Large B-Cell Lymphoma: Study from an Oncology Centre in South India

Immunohistochemical Markers of Tumor Microenvironment as Prognostic Predictors in Diffuse Large B-Cell Lymphoma: Study from an Oncology Centre in South India

Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis

Discovery and application of immune biomarkers for hematological malignancies

Contact Info

Product

Resources

About